Urolithin B

Ergogenic / Muscle

Muscle and metabolic health positioning

Reading this compound Reference only

Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.

Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.

Mechanism & Use

Compound type: Postbiotic small molecule
Primary mechanism: Muscle protein synthesis and mitochondrial modulation
Primary market use: Muscle/longevity

Pharmacology

Molecular weight (Da): 212.2
Oral bioavailability: Oral; variable
Half-life: ~2–12 h small-molecule class estimate
Route tags: Route-dependent / verify
Evidence level: Preclinical
Clinical status: Research
Value-for-money score: 5 / 10

Reported protocol signal

No popular protocol verified yet; keep as reference compound until protocol signal is added.

For orientation only. See disclaimer — always consult a licensed clinician before use.

Notes

Less developed than urolithin A

Sources

https://pubmed.ncbi.nlm.nih.gov/